Journal of Pharmaceutical Investigation

  • 제40권1호
  • /
  • Pages.15-21
  • /
  • 2010
  • /
  • 2093-5552(pISSN)
  • /
  • 2093-6214(eISSN)
한국약제학회 (The Korean Society of Pharmaceutical Sciences and Technology)
권호 표지
DOI QR코드

DOI QR Code

시부트라민 신규염을 이용한 새로운 시부트라민 제제의 개발

Development of Pharmaceutical Dosage Form with New Sibutramine Salt

  • 발행 : 2010.02.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Sibutramine is an orally administered centrally-acting antiobesity agent and inhibits both noradrenaline(norephinephirine) and serotonin(5-HT) reuptake. These effects are contributed by its active metabolites, M1 and M2. However, as the free base form of sibutramine is an oil form in room temperature, it had the problem of handling and stability. Thus, this drug should be used in the form of acid salt form in the pharmaceutical application. Unfortunately, anhydrous sibutramine hydrochloride is highly hygroscopic and unstable. In order to solve the hygroscopicity of the anhydrous salt form, another sibutramine acid salt form must be developed as a hydrate form. In this study. to overcome these problems, various of sibutramine acid salt forms were prepared with the pharmaceutically available salts such as maleate, esylate, mandelate, camsylate, besylate, salicylate, tartrate, isethionate and malate forms, and their physicochemical properties were investigated. Sibutramine malate was selected for excellent solubility and stability among the listed salt forms above. Its pharmacokinetic parameters were evaluated in rats comparing with sibutramine HCl, resulting in similar parameters. In vitro dissolution study of sibutramine malate-loaded capsule was performed comparison with commercial product ($Reductil^{(R)}$) in pH 1.2, pH 4.0, pH 6.8 and water medium. Our results indicated that there were no significant differences in their dissolution profiles were similar in all tested medium. Thus, sibutramine malate-loaded capsule should be a potential candiate due to its excellent solubility, good stability and biosimilar absorption.

키워드

참고문헌

  1. B.J. Rolls, C.J. Shide, M.L. Thorwart and J.S. Ulbrecht, Sibutramine reduces food intake in nondieting women with obesity. Obes. Res., 6, 1-11 (1998). https://doi.org/10.1002/j.1550-8528.1998.tb00308.x
  2. D.L. Hansen, S. Toubro, M.J. Stock, I.A. Macdonald and A. Astrup, Thermogenic effects of sibutramine in humans, Am. J. Clin. Natr., 68, 1180-1186 (1998). https://doi.org/10.1093/ajcn/68.6.1180
  3. W.R. Buckett, P.C. Thomas and G.P. Luscombe, The pharmacology of sibutramine hydrochloride (BTS 54 524) a new antidepressant which induces rapid noradrenergic downregulation, Prog. Neuropsychopharmacol. Biol. Psychiatry.,12(5), 575-584 (1988). https://doi.org/10.1016/0278-5846(88)90003-6
  4. M. Weintraub, A. Rubio, A. Golik, L. Byrne and M.L. Scheinbaum, Sibutramine in weight control: a dose-ranging efficacy study, Clin. Pharmacol. Ther., 50(3), 330-337 (1991). https://doi.org/10.1038/clpt.1991.144
  5. G.P. Luscombe, N.A. Slater, M.B. Lyons, R.D. Wynne, M.L. Scheinbaum and W.R. Buckett, Effect on radiolabeledmonoamine uptake in vitro of plasma taken from healthyvolunteers administered the antidepressant sibutramine HCl,Psychopharmacology, 100, 345-349 (1990). https://doi.org/10.1007/BF02244604
  6. S.C. Cheetham, J.A. Viggers, N.A. Slater, D.J. Heal and W.R. Buckett, [$^3H$]Paroxetine binding in rat frontal cortex strongly correlates with [$^3H$]5-HT uptake: effect of administration of various antidepressant treatments, Neuropharmacology, 32, 737-743 (1993). https://doi.org/10.1016/0028-3908(93)90181-2
  7. S.C. Cheetham, J.A. Viggers, S.A. Butler, M.R. Prow and D.J. Heal, [$^3H$]Nisoxetine-A radioligand for noradrenaline reuptake sites: correlation with inhibition of [$^3H$]noradrenalineuptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology, 35, 63-70 (1996). https://doi.org/10.1016/0028-3908(95)00134-4
  8. H.C. Jackson, M.C. Bearham, L.J. Hutchins, S.E. Mazurkiewicz, A.M. Needham and D.J. Heal, Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat, Br. J. Pharmacol., 121, 1613-1618 (1997a). https://doi.org/10.1038/sj.bjp.0701311
  9. S.C. Cheetham, C.J. Kettle, K.F. Martin and D.J. Heal, $D_1$ receptor binding in rat striatum: modification by various $D_1$ and $D_2$ antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function, J. Neural Transm., 102, 35-46 (1995). https://doi.org/10.1007/BF01276563
  10. H.C. Jackson, A.M. Needham, L.J. Hutchins, S.E. Mazurkiewicz and D.J. Heal, Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat, Br. J. Pharmacol., 121, 1758–1762 (1997b). https://doi.org/10.1038/sj.bjp.0701312
  11. M.J. Stock, Sibutramine: a review of the pharmacology of a novel anti obesity agent, Int. J. Obes., 21 (Suppl. 1), S25-S29 (1997).
  12. I.P. Connoley, Y.L. Liu, I. Frost, I.P. Reckless, D.J. Heal and M.J. Stock, Thermogenic effects of sibutramine and its metabolites. Brit. J. Pharmacol., 126, 1487-1495 (1999). https://doi.org/10.1038/sj.bjp.0702446
  13. I.P. Connoley, I. Frost, D.J. Heal and M.J. Stock, Role of beta-adrenoceptors in mediating the thermogenic effects of sibutramine, Brit. J. Pharmacol., 117, 170 (1996). https://doi.org/10.1111/j.1476-5381.1996.tb15170.x
  14. Z. Abolfathi, J. Couture, F. Vallee, M. LeBel, M. Tanguay and E. Masson, A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J. Pharm. Pharmaceut. Sci., 7(3), 345-349 (2004).
  15. 더 부츠 캄파니 피엘씨, 1-(1-아릴사이클로부틸)알킬아민 유도체의 제조방법, 대한민국특허청, 10-1982-0001506
  16. 더 부츠 캄파니 피엘씨, N,N-디메틸-1-(1-(4-클로로페닐)사이클로부틸)-3-메틸부틸아민 염산염 일수화물의 제조방법, 대한민국특허청, 10-1986-0010764
  17. 한미약품, 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는 약학조성물, 대한민국특허청, 10-2003-0053752
  18. 유한양행, 시부트라민을 함유하는 약제학적 조성물, 대한민국 특허청, 10-2005-0080825
  19. 한올제약, 용해도와 용출률이 향상된 시부트라민 함유 경구투여용 고체분산체, 대한민국특허청, 10-2006-0061063